Singapore markets open in 2 hours

Sesen Bio, Inc. (SESN)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.4140-0.0191 (-4.41%)
At close: 04:00PM EDT
0.4250 +0.01 (+2.66%)
After hours: 06:22PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.4331
Bid0.4121 x 1100
Ask0.4250 x 800
Day's range0.4111 - 0.4490
52-week range0.3650 - 6.0400
Avg. volume3,871,626
Market cap82.578M
Beta (5Y monthly)0.68
PE ratio (TTM)N/A
EPS (TTM)-0.0020
Earnings date08 Aug 2022 - 12 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1.78
  • Zacks

    CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs

    While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

  • Zacks

    Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod

    Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.

  • Business Wire

    Sesen Bio Reports First Quarter 2022 Financial Results and Business Update

    CAMBRIDGE, Mass., May 09, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2022. During the quarter, the Company continued to engage with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for Vicineum™ for the treatment